SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.

The trials of SLGT2 inhibitors in type 2 diabetes suggested a potential benefit of these drugs in patients with heart failure. When randomized trials confirmed their benefit in heart failure with reduced ejection fraction, attention turned to heart failure with preserved ejection fraction (HFPEF). In the EMPEROR-Preserved trial the SGLT2 inhibitor empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure (HR 0.79 95%CI 0.69-0.9, P < .001). This was driven by a reduction in worsening HF events. SGLT2 inhibitors are likely to become the new standard of care in patients with HFPEF.